Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03088826
Other study ID # 2017-01-05
Secondary ID
Status Completed
Phase Phase 2
First received
Last updated
Start date August 18, 2017
Est. completion date December 22, 2020

Study information

Verified date August 2020
Source Maimonides Medical Center
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Oxycodone and Hydrocodone are the most commonly used oral opioid analgesics in the emergency department and in outpatient settings. Both medications have a very high potential for abuse due to the prominence of the euphoric effect (abuse liability) and relative lack of "bad "or "negative" effects (likeability). The highly addictive properties of these medications lead to recurrent ED visits for repetitive dosing and prescribing that may lead to abuse, misuse, development of dependence and addiction, and, most importantly, death due to overdose. In contrast, several research papers demonstrated that administration of MSIR results in similar analgesic efficacy to Oxycodone and Hydrocodone but with significantly less euphoric and rewarding associated effects. In addition, consumption of large doses of MSIR leads to dysphoria, vomiting and sedation ("negative effects"). To the investigators' knowledge, there are no randomized controlled trials in the ED that directly compared analgesic efficacy of MSIR to Percocet


Description:

The investigators' hypothesis is that MSIR coupled with acetaminophen will have similar if not better analgesic efficacy at 30 minutes and 1 hour than oxycodone coupled with acetaminophen for acute painful conditions in the emergency department. This study will be a double-blind randomized clinical trial evaluation analgesic efficacy of orally administered MISIR+acetaminophen in comparison to Oxycodone+acetaminophen for treating pain. Patients will be enrolled from a single ED in a tertiary academic center. Patients based on inclusion criteria will be randomized to receive either 1 tablet of 15mg PO morphine sulfate immediate release combined with 650mg of Acetaminophen or 1 tablet 10mg Oxycodone combined with 650 mg Acetaminophen. All drugs will be crushed and given to the subjects in blinded fashion. Patients, physicians, nurses and research assistants will be blinded to drug assignment throughout the study. Medication will be prepared by on site pharmacist. Pain will be reassessed at both 30 minutes, 45 minutes and 1 hour with the primary outcome of reduction in pain score by 1.3 points at 60 minutes. Assuming a 1.7 pain difference is minimally significant clinically with standard deviation of 3.0 (based on a previous study of morphine analgesia), a minimum of 50 patients per group will be needed for 80% power with alpha equal to 0.05. Secondary outcomes will include any reported adverse effects; the requirement of additional analgesia. Generalized likability and chance of repeated use will be reported by using a visual analogue scale with following questions: "Do you feel any DRUG EFFECT?" "Do you LIKE the drug?" "How HIGH are you?" "Does the drug have any GOOD EFFECTS?" "Does the drug have any BAD EFFECTS?" "How much do you DESIRE the medication?" " Does the drug make you have UNPLEASANT THOUGHTS?" "Does the drug make you have UNPLEASANT BODILY SENSATIONS?" "Does the drug make you feel IRRITATED?" "Does the drug make it DIFFICULT TO CONCENTRATE?" The patients will respond by positioning an arrow along a 100-point line labeled with "not at all" at one end and "extremely" at the other. Data will be analyzed by intention to treat and will include frequency distributions, and Student's T-test to assess a difference in pain scores and vital signs. The chi-square test will assess the presence or absence of side effects between the two groups. Statistical analyses will be conducted by the research manager and the hospital senior biostatistician who will be independent of all data collection.


Recruitment information / eligibility

Status Completed
Enrollment 80
Est. completion date December 22, 2020
Est. primary completion date December 22, 2020
Accepts healthy volunteers No
Gender All
Age group 18 Years to 64 Years
Eligibility Inclusion Criteria: - ages 18-64, - present to the Emergency department with moderate-to-severe acute pain that warrants an oral opioid analgesic. - pain score is above 5 and are deemed to require oral opioid at the discretion of the attending physician. - Painful conditions will include but will not be limited to acute traumatic/non-traumatic musculoskeletal pain, renal colic pain, dental pain. Exclusion Criteria: - age <18, age >64, - subjects who received long acting opioids within 24 hours of presenting to ED - received short acting analgesics within 4 hours, - chronic pain, - pregnant patients, - patient refusal, - altered mental status, - known allergy to either morphine or oxycodone or acetaminophen, - history of substance and opioid abuse, - unstable vital signs, acute psychosis or incarceration. - subjects who received long acting opioids within 24 hours of presenting to ED; - chronic pain"

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Morphine Sulfate
15mg PO morphine sulfate
Oxycodone
10mg Oxycodone
Acetaminophen
650 mg Acetaminophen

Locations

Country Name City State
United States Maimonides Medical Center Brooklyn New York

Sponsors (1)

Lead Sponsor Collaborator
Antonios Likourezos

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Pain Reduction at 60 Minutes (Baseline Pain Score - Pain Score at 60 Minutes) The reduction of pain at 60 minutes from baseline: The pain scale ranges from 0 to 10 with 0 being no pain, 5 being moderate pain and 10 being very severe pain. 60 minutes
See also
  Status Clinical Trial Phase
Completed NCT03334929 - Virtual Reality Distraction for Anxiety Reduction During Trigger Points Procedures in Pain Medicine Clinic N/A
Recruiting NCT06129383 - The Effect of Adding PIFP Block to SAP Block on Postoparative Pain Management in Patient Planned for Breast Surgery N/A
Completed NCT06054945 - Clinical Impact of IPACK Block Addition to Suprainguinal Fascia Iliaca Block
Active, not recruiting NCT02276495 - Can Single-Injection Adductor Canal Blocks Improve PostOp Pain Relief in Patients Undergoing Total Knee Arthroplasty? N/A
Completed NCT04094246 - Battlefield Acupuncture Following Shoulder Surgery N/A
Completed NCT05514236 - Effect of Virtual Reality and Music Therapy on Pain Relief in Outpatient Hysteroscopy N/A
Recruiting NCT04809935 - EUS-Coeliac Plexus Block Versus Radiofrequency Ablation in Pain Relief of Patients With Malignancy Phase 4
Not yet recruiting NCT05492903 - COMmunity of Practice And Safety Support for Navigating Pain (COMPASS-NP) N/A
Not yet recruiting NCT04328805 - Pain Reduction and Changes in Upper Limb Function Produced by an Ibuprofen Treatment in Carpal Tunnel Syndrome. Phase 4
Completed NCT02922101 - Evaluation of the Effectiveness of an Audit and Feedback Intervention With Quality Improvement Toolbox in Intensive Care N/A
Completed NCT01541293 - Intrauterine Lidocaine for Laminaria Phase 1
Not yet recruiting NCT01059487 - Bringing Acute and Wellness Care to Underserved Populations Using Traditional Chinese Medicine Phase 0
Completed NCT03290378 - Tramadol Versus Placebo in the Management of Postoperative Pain Following Bunionectomy Phase 3
Recruiting NCT05794828 - Erector Spinae Regional Anesthesia for Pain Control Early Phase 1
Active, not recruiting NCT04109885 - Paracervical Injection for Headache in the Emergency Department Phase 2
Recruiting NCT05857202 - Oxidative Stress and Inflammation Biomarkers in Surgically Treated Patients With Laryngeal Cancer
Recruiting NCT03851042 - Virtual Reality for Postoperative Pain After Laparoscopic Hysterectomy N/A
Completed NCT04566536 - NoL Monitor Performances of Nociceptive and Non-nociceptive Stimuli Discrimination During Robotic Surgery
Completed NCT03471390 - Improving Pain Management in Nursing Homes: a Pilot Study N/A
Enrolling by invitation NCT02995278 - Usage and Plan of Care Changes Due to Drug Screenings